Clinical Edge Journal Scan

Black women show higher rates of three breast cancer subtypes


 

Key clinical point: Breast cancer subtypes may be associated with race and ethnicity; certain subtypes were significantly more common in Black women and infiltrating duct carcinoma compared to White women, but lobular carcinoma, and tubular adenocarcinoma were less common in Hispanic women compared to nonHispanic White women.

Major finding: The incidence of HR-negative and ERBB2-positive; HR-positive and ERBB2-positive; and triple negative breast cancer was significantly higher among Black women compared to nonHispanic White women, but the incidence of the HR-positive and ERBB2-negative subtype in Black women was lower (incidence rate ratios of 1.12, 1.46, 2.07, and 0.86, respectively).

Study details : The data come from a population-based cohort study of 239,211 women with breast cancer diagnosed between January 1, 2010, and December 31, 2015.

Disclosures: The study was supported by grants to the researchers from several organizations including the Natural Science Foundation of China, the Beijing Municipal Natural Science Foundation, the Special Research Fund for Central Universities, Peking Union Medical College, the Beijing Hope Run Special Fund of Cancer Foundation of China, and the PhD Innovation Fund of Cancer Hospital, Chinese Academy of Medical Sciences. The researchers had no financial conflicts to disclose.

Citation: Kong X et al. JAMA Netw Open. 2020 Oct 19. doi:10.1001/jamanetworkopen.2020.20303.

Recommended Reading

Cancer therapy affects sexual health in most patients
MDedge Hematology and Oncology
SRS instead of WBRT for patients with multiple brain metastases
MDedge Hematology and Oncology
New estimates for breast cancer risk with HRT
MDedge Hematology and Oncology
One-month delay in cancer treatment linked to increase in mortality
MDedge Hematology and Oncology
Study supports genetic testing in older women with breast cancer
MDedge Hematology and Oncology
New cancer drugs may have saved more than 1.2 million Americans
MDedge Hematology and Oncology
‘Test all patients with cancer’: One in eight have inherited mutations
MDedge Hematology and Oncology
Pembrolizumab approved for triple-negative breast cancer
MDedge Hematology and Oncology
Using telehealth to deliver palliative care to cancer patients
MDedge Hematology and Oncology
Pregnancy outcomes ‘favorable’ after BRCA breast cancer treatment
MDedge Hematology and Oncology